Poland· PL-100156696
Mircera
A methoxy polyethylene glycol-epoetin beta product containing methoxypolyethylene glycolum-epoetinum beta, registered in Poland by Roche Registration GmbH. The same ATC class is registered in 12 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Methoxy polyethylene glycol-epoetin beta is registered in 12 of 19 countries.
Countries holding a registration under ATC B03XA03 (methoxy polyethylene glycol-epoetin beta), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 8 of them publish a price we can compare per daily dose
Methoxy polyethylene glycol-epoetin beta · ATC B03XA03
12 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of methoxy polyethylene glycol-epoetin beta costs, country by country.
Normalised to the WHO defined daily dose (4 mcg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Methoxy polyethylene glycol-epoetin beta · price per daily dose (4 mcg)
USD · FX 28 Sept 2026
- CH Switzerland$10.18
The record
At a glance
URPL (Poland)- Active substance
- Methoxypolyethylene glycolum-epoetinum beta
- Manufacturer
- Roche Registration GmbH
- Country
- Poland (PL)
- ATC code
- B03XA03
- ATC class
- Methoxy polyethylene glycol-epoetin beta
- Defined daily dose
- 4 mcg, P
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 1
- gtin05909990052868
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same class
Other records under B03XA03
Methoxy polyethylene glycol-epoetin beta, as other registers publish it.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/fdf5cb89-43c2-4c01-a35b-a6876ff19088 GET /v1/drugs/fdf5cb89-43c2-4c01-a35b-a6876ff19088?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Roztwór do wstrzykiwań",
"source": "urpl",
"strength": "75 mcg/0,3 ml (250 mcg/ml)",
"packaging": "05909990052868 ¦ Rpz ¦ EU/1/07/400/009 ¦ 36223\n1 amp.-strzyk. 0,3 ml\nRpz ¦ EU/1/07/400/024 ¦ 107009\n3 amp.-strzyk. 0,3 ml",
"substance": "Methoxypolyethylene glycolum-epoetinum beta 250 mcg/ml",
"common_name": "Methoxypolyethylene glycolum-epoetinum beta",
"pl_product_id": "100156696",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about methoxy polyethylene glycol-epoetin beta.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.